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ABSTRACT
This study was aimed to evaluate the correlation between the polymorphisms of the UDP-glucuronosyltransferases1A7 (UGT1A7)
gene and the risk of lung carcinogenesis in the Taiwanese population. A total of 230 lung cancer patients and 230 age- and gender-matched
healthy individuals were enrolled in this case control study. UGT1A7*1 was defined as a high activity allele, while UGT1A7*2, UGT1A7*3
and UGT1A7*4 were categorized as low activity alleles. The relationship between EGFR mutations and UGT1A7 polymorphisms was
investigated in this study. The frequency of UGT1A7*2 and UGT1A7*3 was significantly higher in the lung cancer group than in the
control group (p = 0.03, odds ratio (OR) = 1.44, 95% confidence interval (CI) = 1.04 - 1.99 for UGT1A7*2; and p = 0.01, OR = 1.56,
95% CI = 1.11 - 2.18 for UGT1A7*3). The frequency of lower activity alleles was significantly higher in the lung cancer group than in
the control group (p = 0.03, OR = 1.58, 95% CI = 1.04 - 2.40 for the high-activity allele/low-activity allele (H/L) group; and p < 0.01,
OR = 2.23, 95% CI = 1.29 - 3.84 for the low-activity allele/low-activity allele (L/L) group). This difference was only significant in the
male subgroup, with odds ratio of 1.87 (95% CI = 1.05 - 3.36, p = 0.03) for the H/L group and 2.638 (95% CI = 1.28 - 5.42, p < 0.01) for the
L/L allele group. Yet, pathologic type and epidermal growth factor receptor (EGFR) mutations did not affect the distribution of UGT1A7
in the patient group. The results suggested that the polymorphisms of the metabolic gene, UGT1A7, may contribute to reduced enzyme
activity and subsequently affect the detoxification of carcinogens. It is therefore concluded that UGT1A7 polymorphism is associated
with lung carcinogenesis for the Taiwanese population.
Key words: UGT1A7 polymorphisms, lung cancer, risk factor, EGFR mutation, gene, enzyme

INTRODUCTION
Lung cancer is responsible for 1.3 million deaths worldwide annually(1). It is ranked the number-one cause of all
cancer deaths in both men and women in Taiwan(2). Tobacco
smoking is an important risk factor for lung cancer. In
particular, the activity of xenobiotic enzymes has been linked
to the modulation of risk(3,4). Tobacco smoke contains more
than 60 known carcinogens such as nicotine, nitrosamines
and polycyclic aromatic hydrocarbons. These carcinogens are
metabolized by both hepatic and extrahepatic enzymes, such
as cytochrome P450 enzymes or uridine 5'-diphospho-glucuronosyltransferases (UGTs)(4-6). The UGT1A gene complex
* Author for correspondence. Tel: +886-2-29307930 ext. 1157;
Fax: +886-2-86621163; E-mail: shawn@tmu.edu.tw

is located on human chromosome 2 at 2q37, which encoded
nine functional proteins (UGT1, UGT1A3-UGT1A10)(7,8).
UGT1A7, a member of the UGT1 family, plays important
roles in the conjugation and detoxification of several tobacco
carcinogens, including 4-(methylnitrosamino)-1-(3-pyridyl)1-butanone (NNK)(9) and benzo-[α]-pyrene (BaP)(10,11). The
catalytic activity of UGT1A7 is determined by its polymorphisms at codon 129, 131 and 208. UGT1A7*1 (wild type) has
the highest activity, followed by UGT1A7*2 (K129K131W208),
UGT1A7*4 (N129R131R 208) and UGT1A7*3 (K129K131R 208)(11).
In recent reports in Japan, the presence of UGT1A7 polymorphisms has been suggested to be a risk factor in orolaryngeal
cancer(12), proximal GI tract cancer(13), hepatocellular carcinoma(14), colorectal cancer(15,16), pancreatic cancer(17) and
lung cancer(6).
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Non-smoking women have a high incidence rate of
lung adenocarcinoma in Taiwan and other Asian countries,
indicating that there may be risk factors other than smoking,
which leads to lung cancer. Alteration of genes such as overexpression of oncogenes(18), silencing of tumor suppressor
genes(19,20) and defects in DNA repair mechanism(21) may
also contribute to lung carcinogenesis. Most Asian female
patients with lung cancer are non-smokers and they often
represent a distinct type. Adenocarcinoma and epidermal
growth factor receptor (EGFR) overexpression are the most
predominant(22). EGFR has been identified as an important
prognostic factor in the advanced stage of lung cancer. The
clinical outcomes after the therapy of EGFR tyrosine kinase
inhibitor can be predicted by EGFR mutations(23).
The purpose of this study was to examine the relationship between UGT1A7 polymorphism and EGFR mutations in
the Taiwanese population and to determine whether UGT1A7
polymorphisms are potentially associated with a higher risk
of lung cancer. The distribution of UGT1A7 alleles, genotypes and their predicted phenotypes in lung cancer patients
were compared with the controls. EGFR mutations in the
lung cancer patients were also analyzed.

MATERIALS AND METHODS
I. Patients and Clinical Specimens
A total of 230 lung cancer patients from Wan Fang
Hospital, Taipei Medical University were studied between
2004 and 2009 according to a protocol approved by the
Institutional Review Board (IRB). All patients who
participated in this study signed the letter of informed
consent and had the willingness and ability to give informed
consent. A confirmed diagnosis of primary lung cancer and
ages between 18 and 90 were the specific inclusion criteria
in this study. The peripheral blood and clinical information of the patients were collected after obtaining informed
consent. Of the 230 patients, 197 cancer-containing tissues
were collected from bronchoscopic biopsies (70.6%), proven
malignant pleural effusion (26.9%) or lobectomy (2.5%). A
total of 230 healthy volunteers who were matched with the

cancer patients by age and sex, and had no history of cancer
or disease associated with UGT1A7 polymorphism, such as
Gilbert’s syndrome, pancreatic diseases, hyperbilirubinemia
and hepatitis C, were randomly recruited into the study over
the same period of time.
II. Determination of Genotypes
In order to determine the UGT1A7 genotyping, genomic
DNA from peripheral blood mononuclear cells was extracted
by proteinase K digestion, followed by the conventional
phenol-chloroform method as previously described(24).
Genomic DNA from paraffin-embedded tissues was
extracted by commercial kits (DEXPATTM, Takara, Shiga,
Japan) for the detection of EGFR mutation.
The identification of each subject’s UGT1A7 alleles
was performed by PCR-restriction fragment length polymorphism (RFLP) analysis for the nucleotide 622 polymorphic sites and nested PCR was performed for nucleotide
387 polymorphic positions. The use of these combined
analyses allowed the differentiation of all genotypes formed
by UGT1A7*1, UGT1A7*2, UGT1A7*3 and UGT1A7*4
alleles, except UGT1A7*1/UGT1A7*3 and UGT1A7*2/
UGT1A7*4. Since the frequency of the UGT1A7*4 allele
in the Chinese population was less than 3%(11,17,25), the
subjects who exhibited either the UGT1A7*1/UGT1A7*3 or
UGT1A7*2/UGT1A7*4 genotypes were considered to have
the UGT1A7*1/UGT1A7*3 genotypes, according to previous
reports(12,26).
The PCR reaction for generating UGT1A7 622T→C
and UGT1A7 387T→G DNA fragments was performed in a
thermal cycler (PC806, ASTEC, Japan) in the presence of
0.2 mM of dNTPs (Protech, Taiwan), 1 x Taq buffer (Protech,
Taiwan), 0.04 U/µL of Taq polymerase (Protech, Taiwan),
1 µL of forward and reverse primers (Table 1) and 0.5 µL of
DNA prepared in a total volume of 25 µL(26). The reaction
was performed under the following conditions: 1 cycle at
94°C for 3 min, followed by 34 cycles at 94°C for 30 s; 55°C
for 30 s; 72°C for 1 min, and 1 cycle at 72°C for 10 min, and
then cooling down at 4°C. Primary and nested PCR amplifications were utilized to determine UGT1A7 387T→G DNA
fragments and to further confirm by restriction enzymes

Table 1. Primer sequences used in UGT1A7 genotyping
Position (cDNA)

Primers

Sequence

Restriction Enzyme

Result (bp)

622 TàC

U7F3

5’-TGTCCCCAGACTTCTCTTAG-3’

RsaI

WT: 447

U7R3

5’-GCTACCCAACAATTAAGTGA-3’

387 TàG

1st PCR
U7F1

5’-TGAATGAATAAGTACACGCC-3’

U7R2

5’-TAGGGGCAAAATAAATGTTC-3’

MT: 54+393

Nested PCR
387F

5’-AAATTGCAGGAGTTTGC*TTA-3’

387R

5’-TGGCAAAATATTCCCCTGGC-3’

AflII

WT: 159
MT: 142+17
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digestion. The UGT1A7 622T→C DNA fragments were
digested by RsaI (Promega, USA). DNA fragments were
separated by 3% agarose gel electrophoresis at 100 V for
40 min. While UGT1A7 387T→G DNA fragments were
digested by AflIII (New England BioLabs, UK), sizes were
fractioned by 8% polyacrylamide gel electrophoresis at 100 V
for 95 min. Both were then visualized by ethidium bromide
staining. According to previous literatures on UGT1A7
enzyme activity, UGT1A7*1 was defined as a higher activity
allele and UGT1A7*2, UGT1A7*3 and UGT1A7*4 were categorized as lower activity alleles(10,11). The predicted phenotypes were categorized into high-activity allele/high-activity
allele (H/H), high-activity allele/low-activity allele (H/L),
and low-activity allele/low-activity allele (L/L)(27).
The detection of EGFR mutations in exon 18-21 was
performed by PCR. Table 1 represents the primers used in
the study and the representative results have been previously
described(28). Direct sequencing of the mutant bands was
also used to validate the accuracy of detection.
III. Statistical Analysis
SPSS 13.0 (SPSS Inc, Chicago, IL, USA) for Windows
was used to analyze continuous and categorical data. The
continuous data were analyzed by Student’s t-test. Multivariable logistic regression was applied to calculate the odds ratios
for comparing the differences in the predicted phenotypes,
genotypes and variant allele frequencies between patients
and normal controls. Two-tailed p < 0.05 was considered as
statistically significant. The Hardy-Weinberg equilibrium of
alleles at individual loci was also evaluated.

RESULTS
I. Clinical and Histological Data
Table 2 depicts the demographic characteristics
of cancer patients and normal controls. Both groups of
lung cancer patients and healthy individuals consisted of
128 males (55.7%) and 102 females (44.3%). The majority
of patients (n = 223, 96.9%) were diagnosed with non-small
cell lung cancer (NSCLC) at an advanced stage. Among the
patients, 77 (33.5%) were diagnosed with stage III B and 113
(49.1%) with stage IV.
II. Association of UGT1A7 Polymorphism with Lung Cancer
The alleles at the individual loci fulfilled the HardyWeinberg distribution in both patient and control groups
(p > 0.05). The frequencies of UGT1A7*2 and UGT1A7*3
were significantly higher in the lung cancer group.
(p = 0.03, odds ratio (OR) = 1.44, 95% confidence interval
(CI) = 1.04 - 1.99 for UGT1A7*2; and p = 0.01, OR = 1.56,
95% CI = 1.11 - 2.18 for UGT1A7*3, respectively, Table 3).
Subgroup analysis that compared male lung cancer patients
with male controls revealed a similar result, with an odds

ratio of 1.59 (95% CI = 1.06 - 2.43, p = 0.03) for UGT1A7*2,
and 1.63 (95% CI = 1.05 - 2.54, p = 0.03) for UGT1A7*3.
However, the frequencies of UGT1A7*2 and UGT1A7*3 were
not significantly different between the female lung cancer
patients and their corresponding controls.
There was a significant difference in the distribution of
genotypes between the patients and controls. Cancer patients
had a higher percentage of UGT1A7*1/*3, UGT1A7*2/*2 and
UGT1A7*3/*3 genotypes than the controls, suggesting that
genotypes of lower activity might be a potential risk factor
for the development of lung cancer (p = 0.02, OR = 1.83, 95%
CI = 1.10 - 3.04 for UGT1A7*1/*3; p < 0.01, OR = 3.89, 95%
CI = 1.44 - 10.51 for UGT1A7*2/*2; and p = 0.04, OR = 2.92,
95% CI = 1.04 - 8.20 for UGT1A7*3/*3). Results of further
analysis on the predicted phenotypes showed that the
frequency of cancer patients having at least one low-activity
allele was significantly higher than the controls (p = 0.03,
OR = 1.58, 95% CI = 1.04 - 2.40 for the H/L group; and
p < 0.01, OR = 2.23, 95% CI = 1.29 - 3.84 for the L/L group,
Table 4).
Comparing the subgroup analysis of male patients
with that of male controls, similar results were revealed
for the H/L and L/L allele groups, with an OR of 1.87 (95%
CI = 1.05 - 3.36, p = 0.03) and 2.64 (95% CI = 1.28 - 5.42,
p < 0.01), respectively. However, this trend was not observed
in female patients. These results suggested a positive

Table 2. Demographic characteristics of enrolled patients with lung
cancer and the control participants
Lung cancer
(n = 230)

Control
(n = 230)

Male

128 (55.7)

128 (55.7)

Female

102 (44.3)

102 (44.3)

Age (year)

67.74 ± 12.23

67.70 ± 13.15

Sex (%)

Pathology Classification (%)
Non-small cell lung cancer
Adenocarcinoma

223 (96.9)
181 (78.8)

Squamous cell carcinoma

32 (13.9)

Others

10 (4.3)

Small cell lung cancer

7 (3.0)

Lung cancer stage (%)
IA

14 (6.1)

IB

9 (3.9)

IIA

2 (0.9)

IIB

5 (2.2)

IIIA

3 (1.3)

IIIB

77 (33.5)

IV

113 (49.1)

Limited (small cell type)

1 (0.4)

Extensive (small cell type)

6 (2.6)
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Table 3. Comparison of the allelic frequency of UGT1A7 between lung cancer patients and the control group
Allele Frequency

Lung cancer (n = 460)

Control (n = 460)

OR

95% CI

p - value

*1

0.516 (237)

0.613 (282)

ref

-----

-----

*2

0.250 (115)

0.207 (95)

1.44

1.04 - 1.99

0.03*

*3

0.230 (106)

0.176 (81)

1.56

1.11 - 2.18

0.01*

*4

0.004 (2)

0.004 (2)

1.19

0.17 - 8.51

0.86

*1

0.554 (113)

0.627 (128)

ref

-----

-----

*2

0.225 (46)

0.202 (41)

1.27

0.78 - 2.08

0.34

*3

0.211 (43)

0.162 (33)

1.48

0.88 - 2.48

0.14

*4

0.010 (2)

0.009 (2)

1.13

0.16 - 8.17

0.90

*1

0.484 (124)

0.602 (154)

ref

-----

-----

*2

0.270 (69)

0.211 (54)

1.59

1.04 - 2.43

0.03*

*3

0.246 (63)

0.187 (48)

1.63

1.05 - 2.54

0.03*

*4

0.000 (0)

0.000 (0)

-----

-----

-----

Female (n = 204 in each group)

Male (n = 256 in each group)

* p < 0.05 compared with control.

Table 4. Comparison of predicted phenotypes between lung cancer patients and the control group
UGT1A7 Predicted
phenotype

Lung cancer
(n = 230) (%)

Control
(n = 230) (%)

OR

95% CI

p - value
-----

H/H

59 (25.7)

86 (37.4)

ref

-----

H/L

119 (51.7)

110 (47.8)

1.58

1.04 - 2.40

0.03*

L/L

52 (22.6)

34 (14.8)

2.23

1.29 - 3.84

< 0.01*

H/H

31 (30.4)

38 (38.3)

ref

-----

H/L

51 (50.0)

50 (49.0)

1.28

0.70 - 2.37

0.43

L/L

20 (19.6)

13 (12.7)

1.94

0.83 - 4.50

0.13

H/H

28 (21.9)

47 (36.7)

ref

-----

H/L

67 (52.3)

60 (46.9)

1.87

1.05 - 3.36

0.03*

L/L

33 (25.8)

21 (16.4)

2.64

1.28 - 5.42

< 0.01*

Female (n = 102 in each group)
-----

Male (n = 128 in each group)
-----

* p < 0.05 compared with control.

correlation between these alleles and the presence of lung
cancer. These alleles encoded protein with low catalytic
activity of UGT1A may contribute to increased risk of lung
cancer in male but not female patients.
A stratified analysis of smoking rate in the male lung
cancer patients was performed to evaluate the effect of
smoking on these patients. Of the 128 male patients, 108
(85.3%) were smokers. The smoking rates of the male lung
cancer patients were 82.1%, 86.6% and 93.3% in the H/H,
H/L and L/L groups, respectively, showing no statistically
significant difference (p = 0.43). This suggests that smoking
was not the confounding factor for the observed differences
in UGT1A genotypes in males.
Although the frequencies of genotypes and predicted

alleles were different between the lung cancer patients
and the controls, further analysis failed to demonstrate a
significant association between UGT1A7 polymorphisms
and pathologic types or stages. The patient numbers identified with H/H, H/L and L/L UGT1A7 genotypes were 26
(23.0%), 58 (51.3%) and 29 (25.7%) for those with stage
IV NSCLC, and 34 (30.9%), 57 (51.8%) and 19 (17.3%) for
earlier stages of NSCLC, respectively (p = 0.21). Of the 181
patients with adenocarcinoma, 52 (28.7%), 92 (50.8%) and
37 (20.4%) patients were identified with H/H, H/L and L/L
UGT1A7 genotypes, while in other types of lung cancer, the
patient numbers were 8 (16.3%), 28 (57.1%) and 13(26.5%),
respectively (p = 0.19).
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III. Association between UGT1A7 Polymorphism and EGFR
Mutations
Of the 197 tissue samples collected from the cancer
patients, 72 (36.5%) cancer patients showed EGFR mutations. The mutations of exon 19, exon 20 and exon 21
accounted for 36.1% (n = 26), 4.1% (n = 3) and 59.7% (n = 43),
respectively. The results were consistent with prior studies,
which indicated that the female gender and non-smoking
status were risk factors for EGFRmut lung cancer. The
mutation occurred in 46 (51%) out of 91 females and 26
(25%) out of 106 males, showing a positive association
with lung cancer (OR = 3.15, 95% CI = 1.72 - 5.75, p < 0.01).
In addition, the mutation rate was 57.3% (n = 55) in the
non-smokers, which was significantly higher than the
smokers (16.8%, n = 7, p < 0.01; OR = 6.63; 95% CI = 3.43
- 12.82). However, there was no significant difference in the
distribution of UGT1A7 polymorphisms for the patients with
or without EGFR mutations.

DISCUSSION
The relationship between UGT1A7 genotypes and
the risk of lung cancer in the Taiwanese population was
evaluated in this study. Our results were consistent with
a previous Japanese study that showed a strong correlation between the UGT1A7 genotype and lung cancer(6).
In addition to reports revealed by the previous study, our
results indicated that patients with predicted low-activity
phenotypes, i.e. one or two of the UGT1A7*2, UGT1A7*3
and UGT1A7*4 alleles, were associated with an increased
risk of lung cancer in the Taiwanese population. This association was found in the male subgroup for the first time
by subgroup analysis in this study. The stratified analysis
showed that the smoking rates among the three groups
with UGT1A7 H/H, H/L and L/L genotypes were similar,
indicating that smoking was not a confounding factor of
genotype variables. Since the smoking rate of male lung
cancer patients (85.3%) was much higher than the rate of
male adults (35.4%) in Taiwan, the accumulation of tobacco
carcinogens was expected to be increased in those with low
activity of UGT1A7 expression, leading to elevated lung
carcinogenesis in these patients(29).
Our finding was in line with the known consequence
of low UGT1A7 activity, leading to the accumulation of
carcinogens as a result of reduced capacity of conjugation
and detoxification against them. In addition to lung cancer,
low-activity alleles of UGT1A7 have also been implicated in
colorectal cancer(15,16), with dietary carcinogen intake(30),
smoking and alcohol consumption(25) as modifying factors.
Likewise, similar trends have been found in the susceptibility of proximal gastrointestinal tract cancers and
orolaryngeal cancers for the smokers in particular(12,23).
The frequency of the wild type UGT1A7*1 allele in the
present study was more than 50% of the population, which
was similar to previous studies on the UGT1A7 genotypes

in the Chinese, Taiwanese and Japanese populations(6,25,26),
but higher than that in Caucasians(12). This suggested that
ethnic differences in the UGT1A7 genotypes may exist
between Caucasians and Asians.
The association between lung cancer and UGT1A7, a
gene that metabolizes carcinogens from smoking, was not
significant in female patients and this finding is disclosed for
the first time in this report. The finding echoes a previous
molecular epidemiologic discovery on a pathogenesis of lung
cancer unrelated to the detoxication of carcinogens, especially
derived from female patients who smoke(31). The smoking
rate of the female patients was 11.8% and not significantly
different from that of Taiwanese female adults(29), indicating
that the UGT1A7 gene had a low impact on interrupting the
cancer development in the female patients. Previous research
also found that the female gender was a sole risk factor independent of smoking for EGFR mut NSCLC(32). With significantly higher incidence of EGFR mutations found in Asian
female patients as shown in our study and previous reports,
other risk factors and carcinogenesis correlated to EGFR
mutations should be considered to prevent lung cancer in this
subpopulation(33). On the other hand, the suspicion that low
activity alleles of UGT1A7 may be more common among the
patients with EGFR wild type than those with EGFR mutations was ruled out by the observation that the mutations of
EGFR and the polymorphisms of UGT1A7 were unrelated.
No single factor or class of genes shall determine
the development of lung cancer as it is a complex disease
involving several genetic, biological, psychological, social
and environmental factors. For example, inherited germline mutation in tumor suppressor gene P53 significantly
increases the risk of developing lung cancer(19). A higher risk
in non-small cell lung cancer was associated with functional
polymorphism in the promoter region of the MDM2 gene,
one that controls MDM2 transcription and P53 activity(20).
Alteration in DNA repair proteins, such as ERCC2, results
in impaired DNA repair capability and also increases the
risk of lung cancer(21). Apart from UGT1A7, other carcinogen
metabolic genes, such as cytochrome P450, particularly
the CYP1A1 subfamily polymorphisms, are also involved
in increasing the risk of lung cancer(4,5). Individuals with
combined NAT1 rapid and NAT2 slow genotype seemed to
have a significantly higher risk for lung adenocarcinoma(34),
or the NAT2 slow genotype when combined with the GSTM1
null genotype may increase the susceptibility to adduct
formation, gene mutation and lung cancer risk(35). With the
consideration of the significant genes involving the development of lung cancer, better prediction and prevention of the
disease may be achieved. Correlations of toxin-metabolizing
genes and risk factors should be investigated to predict the
risk of lung cancer in future studies.
The results of the current study suggest that UGT1A7
polymorphism is associated with lung cancer in a Taiwanese
subpopulation. Lower activity alleles and predicted phenotypes are significantly associated with an elevated risk of lung
cancer, with the exclusion of female patients. Based on this
observation, the determination of UGT1A7 polymorphisms
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may provide additional information for high risk groups
and support in developing preventive strategies against lung
cancer, especially in male smokers. Further studies on a larger
population should be performed to confirm these findings.
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